News | March 29, 2025
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
Subscribe To Our Newsletter & Stay Updated
